Scarica l'app Stockscreener
1.94
2.51%
-0.05
Dopo l'orario di chiusura:
1.94
Precedente Chiudi:
$1.99
Aprire:
$1.96
Volume 24 ore:
479.99K
Relative Volume:
0.45
Capitalizzazione di mercato:
$273.77M
Reddito:
$15.53M
Utile/perdita netta:
$-52.71M
Rapporto P/E:
-3.8607
EPS:
-0.5025
Flusso di cassa netto:
$-59.00M
1 W Prestazione:
-7.18%
1M Prestazione:
+7.18%
6M Prestazione:
+7.78%
1 anno Prestazione:
-13.78%
Intervallo 1D:
$1.915
$1.96
Intervallo di 1 settimana:
$1.915
$2.125
Portata 52W:
$1.33
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Nome
Proqr Therapeutics N V
Settore
Industria
Telefono
-
Indirizzo
-
Compare PRQR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.94 | 280.83M | 15.53M | -52.71M | -59.00M | -0.5025 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-12 | Ripresa | Oppenheimer | Outperform |
| 2025-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-04-29 | Iniziato | Evercore ISI | Outperform |
| 2025-03-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-01-10 | Iniziato | Oppenheimer | Outperform |
| 2024-10-29 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-11-08 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2023-03-30 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-12-22 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-11 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| 2022-02-11 | Downgrade | Stifel | Buy → Hold |
| 2022-02-01 | Iniziato | Raymond James | Strong Buy |
| 2021-05-03 | Iniziato | Stifel | Buy |
| 2021-03-25 | Reiterato | Citigroup | Buy |
| 2020-11-03 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-03-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-12-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2018-11-15 | Iniziato | Citigroup | Buy |
| 2018-09-19 | Iniziato | Evercore ISI | Outperform |
| 2017-09-26 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-06-20 | Iniziato | Chardan Capital Markets | Neutral |
| 2014-10-15 | Iniziato | Deutsche Bank | Buy |
| 2014-10-13 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Proqr Therapeutics N V Borsa (PRQR) Ultime notizie
Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com
ProQR Therapeutics Initiates AX-0811 Clinical Trial Following First Participant Dosing - Kalkine Media
ProQR Therapeutics N.V.ADR Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com Nigeria
ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com South Africa
ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment - marketscreener.com
ProQR doses first participant in AX-0811 phase 1 trial - Investing.com
ProQR Doses First Participant in Phase 1 Trial of AX-0811 for Cholestatic Liver Diseases - TipRanks
ProQR Announces First Participant Dosed in Phase 1 Study of - GlobeNewswire
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageShould You Sell? - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
ProQR to Participate in Upcoming Investor Conferences in September 2026 - markets.businessinsider.com
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Warrants of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
Certain Common Stock of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts (NASDAQ:PRQR) - Seeking Alpha
Price to sales forward of ProQR Therapeutics N.V. – FWB:0PQ - TradingView
PRQR Looks 1.8% Undervalued on GF Value™ at $2.45 - GuruFocus
PRQR Initiates Coverage by B of A Securities -- Price Target Ann - GuruFocus
ProQR a new buy at BoA on RNA-editing platform - Seeking Alpha
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Analysts at Bank of America - MarketBeat
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com India
BofA Securities initiates ProQR stock with buy on liver therapy - Investing.com
ProQR (PRQR) Levels: Climbs 3.26% to $2.22 in the Latest Session; Key Range - vinanet.vn
HC Wainwright Expects Lower Earnings for ProQR Therapeutics - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
Equities Analysts Set Expectations for PRQR FY2030 Earnings - MarketBeat
H.C. Wainwright reiterates ProQR stock rating on platform data By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates ProQR stock rating on platform data - in.investing.com
ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Hold at Wall Street Zen - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Announces Earnings Results - MarketBeat
ProQR: Q2 Earnings Snapshot - KTVB
ProQR Therapeutics NV earnings beat by €0.03, revenue topped estimates - Investing.com Nigeria
ProQR Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
ProQR Therapeutics NV reports results for the quarter ended June 30Earnings Summary - TradingView
ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results - TipRanks
ProQR Announces Second Quarter 2026 Operating and Financial Results - The Manila Times
ProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline Milestones - Quiver Quantitative
ProQR Therapeutics N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProQR Therapeutics NV expected to post a loss of 11 cents a shareEarnings Preview - TradingView
ProQR Therapeutics (PRQR) Slips 3.5% as Shares Test Key Support ZoneReversal Trade - dars.gov.et
ProQR Therapeutics NV (PRQR) Stock News Today - TradingKey
ProQR Therapeutics NV (PRQR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – MUN:0PQ - TradingView
ProQR Therapeutics (PRQR) CEO de Boer Daniel Anton Buys 200,000 Shares, Signaling Confidence - GuruFocus
ProQR Therapeutics (PRQR) Surges 7% to $1.83 as Buyers Defend Key SupportAnalyst Downgrade Signals - vinanet.vn
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Proqr Therapeutics Insider Bought Shares Worth $353,960, According to a Recent SEC Filing - marketscreener.com
Proqr Therapeutics N V Azioni (PRQR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):